We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Fate Therapeutics Treats First Patient in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support

News   Jun 02, 2009

 
Fate Therapeutics Treats First Patient in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
 
 
 

RELATED ARTICLES

Discovering the Parameters That Govern the Encapsulation of Drugs

News

Researchers at Eindhoven University of Technology and Utrecht University have discovered the parameters that govern the encapsulation of drugs.

READ MORE

New Class of Drugs Could Treat Ovarian Cancer

News

A team of researchers across The University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing.

READ MORE

FDA Approves First Treatment for Postpartum Depression

News

The U.S. Food and Drug Administration today approved Zulresso (brexanolone) injection for intravenous (IV) use for the treatment of postpartum depression (PPD) in adult women. This is the first drug approved by the FDA specifically for PPD.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cell Science

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE